The Enterprise DG of the European Commission retained Charles River Associates to undertake a study investigating whether there is a worldwide crisis in innovation in the pharmaceutical sector, the reasons behind this crisis, and the tools available to kick-start innovation.
The socioeconomic impact of rare diseases: An analysis of the evidence in middle-income countries
Worldwide, it is estimated that over 300 million people are living with one or more of the 6,000 to 8,000 identified rare conditions, yet the impact of rare...